Radius Health, Inc. s trend and data analysis indicates that the stock price has dropped -4.58% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -29.86% . Looking at the past 52 week period, the stock price is up at 18.56% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Radius Health, Inc. has a positive value of 22.25 compared to overall market.Radius Health, Inc. is having a Relative Strength Index of 35.03 which indicates the stock is not yet over sold or over bought based on the technical indicators.
Radius Health, Inc. (NASDAQ:RDUS) has tumbled 7.12% during the past week and has dropped 16.89% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 7.34%. Radius Health, Inc. (NASDAQ:RDUS) has underperformed the index by 17.84% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
For the current week, the company shares have a recommendation consensus of Buy. Radius Health, Inc. (NASDAQ:RDUS) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.14 points or 0.37% at $37.94 with 1,779,302 shares getting traded. Post opening the session at $37.83, the shares hit an intraday low of $37.76 and an intraday high of $38.79 and the price was in this range throughout the day. The company has a market cap of $1,638 million and the number of outstanding shares has been calculated to be 43,186,484 shares. The 52-week high of Radius Health, Inc. (NASDAQ:RDUS) is $59.88 and the 52-week low is $28.
Company has reported several Insider transactions to the SEC, on Jan 27, 2016, Lorraine A. Fitzpatrick (Chief Medical Officer) purchased 200 shares at 49.28 per share price.On Nov 25, 2015, Robert Ward (President & CEO) sold 25,000 shares at 62.76 per share price.On Nov 13, 2015, Gary Hattersley (Chief Scientific Officer) sold 5,683 shares at 75.00 per share price.
Radius Health Inc Last issued its quarterly earnings results on Feb 23, 2017. The company reported $-1.22 EPS for the quarter, beating the analyst consensus estimate by $ 0.09. Analyst had a consensus of $-1.31.During the same quarter in the previous year, the company posted $-0.77 EPS.
Radius Health Inc. is a science-driven biopharmaceutical company. It is focused on developing novel differentiated therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases. The Companys lead product candidate, abaloparatide (BA058), is in development, in both injection (Abaloparatide-SC) and transdermal (Abaloparatide-TD) methods of administration, for the prevention of fractures in post-menopausal women at risk of fracture from osteoporosis. Radius Health Inc. is based in Cambridge, Massachusetts.